Colleen Moretti

Results of the ARASENS trial (NCT02799602) demonstrated that darolutamide plus ADT and docetaxel prolonged overall survival regardless of disease volume or risk.

Combining radiotherapy with next-generation hormonal therapy is a feasible approach to explore in phase 3 trials enrolling patients with high-risk localized or locally advanced prostate cancer, according to an analysis of the phase 3 ATLAS trial.

The study included patients who were Hispanic and from the south Florida region, which was not included in previous studies.

Men who were obese and on active surveillance had worse urinary incontinence compared to non-obese peers through 5 years.

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Patients with prostate cancer have a 20% to 30% incidence of depression and anxiety; however, practicing yoga could improve their quality of life.

“This study highlights a deficiency in urologic oncology [randomized, controlled trials’] to assess smoking status and participants. Given smoking’s effects on treatments, survival, and quality of life, we believe this is an important area that deserves more attention,” said Calvin C. Zhao, MD

Based on findings from the phase 3 CheckMate 9ER trial, the FDA approved nivolumab/cabozantinib for use in the first-line setting for patients with advanced RCC.